Startups
BridgeBio Oncology Therapeutics (BBOT) is a biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 1, 2025 | Omega Funds | omegafunds.com |
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| BridgeBio Oncology Therapeutics | “Leadership Eli Wallace, Ph.D. – CEO Pedro Beltran, Ph.D. – CSO Board of Directors Frank McCormick, Ph.D. (Chair) Neil Kumar, Ph.D. Raymond Kelleher, M.D., Ph.D. Michelle Doig Our Programs bbo-8520, a KRASG12C(ON) inhibitor Phase 1 ONKORAS-... |
Reviews 0
FAQ about BridgeBio Oncology Therapeutics
Who has invested in BridgeBio Oncology Therapeutics?
Parsers VC lists 2 investors of BridgeBio Oncology Therapeutics, among them Omega Funds.
What has the press written about BridgeBio Oncology Therapeutics?
Parsers VC has collected 2 articles mentioning BridgeBio Oncology Therapeutics, among them “BridgeBio Oncology Therapeutics”.
Is BridgeBio Oncology Therapeutics still active?
BridgeBio Oncology Therapeutics is probably closed: its latest activity on Parsers VC dates from Jul 10, 2026.